The number nobody questions

Walk into almost any fitness conversation in 2026 and "10,000 steps a day" will be cited without anyone naming the source. The number is on the default goal screen of every Apple Watch, every Fitbit, every Garmin. It is the bar that workplace step-challenges measure people against. It has, for sixty years, been treated as a roughly evidence-based threshold for "active enough".

It is not. It was a 1965 marketing slogan.

In the run-up to the 1964 Tokyo Olympics, a Japanese physician named Yoshiro Hatano became concerned about rising obesity rates as the country urbanised. Working with a clock-maker called Yamasa, his team launched a pedometer called the Manpo-kei, which translates literally as "10,000-step meter" [1]. The choice of 10,000 had two roots: the Japanese character for 10,000 (万) loosely resembles a walking person, and 10,000 is a memorable round number that fits cleanly into a slogan. There was no underlying dose-response study. Hatano himself later said as much.

The number stuck because it was easy to remember, easy to count toward, and - usefully for the device makers - high enough to make ownership of a step counter feel necessary. It then propagated through corporate wellness, smartphone defaults, and finally became the un-interrogated background assumption it is today. Catherine Tudor-Locke's group at Pennington Biomedical Research Center has spent two decades unpicking it; her 2008 review noted that the 10,000-step target lacked any direct empirical foundation, even though by then it was embedded in public-health messaging in dozens of countries [2].

What is interesting is that the cohort data finally caught up. Between 2019 and 2023, four large prospective studies independently measured step counts via worn accelerometers - not self-report - and followed participants for years. They told a remarkably consistent story, and it was not the 10,000 story.

What a step actually is, biologically

Before getting to the cohort data it is worth being clear what walking is doing physiologically, because the framing of "steps as health units" obscures the underlying mechanism.

A step at typical adult pace requires roughly 0.04 to 0.06 kcal of energy expenditure per kilogram of body mass, depending on stride length and speed. For a 75 kg adult that is about 3 to 5 kcal per 100 steps. Most of that energy is supplied aerobically by the type I (slow-twitch) muscle fibres in the legs and hips, which fits walking neatly into the same metabolic regime as zone 1 to low zone 2 cardio: fat oxidation dominates, lactate accumulation is negligible, the cardiovascular system runs comfortably below ventilatory threshold.

The longevity-relevant effects of doing this several thousand times a day are not from any single step. They are from sustained, low-grade metabolic and vascular loading. Specifically:

  • Endothelial shear stress. Each minute of moderate walking produces sustained vasodilation in the lower-extremity arteries; chronic exposure improves endothelial function and lowers resting blood pressure measurably within weeks. Repeated low-intensity vascular loading is one of the better-evidenced interventions for arterial stiffness reduction in middle-aged adults.
  • Postprandial glucose disposal. Even a 10-minute walk within an hour after a meal blunts the postprandial glucose spike by 12 to 27 percent in healthy adults and considerably more in pre-diabetics. The mechanism is GLUT4 translocation in skeletal muscle - contraction-driven glucose uptake that operates independently of insulin signalling.
  • Lipid clearance. Lipoprotein lipase activity in skeletal muscle drops measurably within 1 to 4 hours of sitting and is restored only by muscle contraction. The published "breaking up sitting time" interventions trade on this mechanism - daily step count is partly a proxy for "not sat for too long at a stretch".
  • Mitochondrial maintenance. Steady low-intensity contraction sustains the signalling cascade (AMPK, PGC-1α) that maintains mitochondrial density in slow-twitch fibres. The dose required is modest but the contraction has to happen.

That last point is why "steps per day" is a more meaningful aggregate than total minutes of structured exercise. A person who runs three times a week but is sedentary in between accumulates considerable cardio-respiratory adaptation but loses the postprandial-glucose, lipoprotein-lipase, and sustained-vascular-loading effects across the long sedentary stretches. The step count is a coarse but useful integration of "how much of the day was the metabolism being asked to do something".

What the mortality data actually says

The cleanest single piece of evidence is the I-Min Lee 2019 paper in JAMA Internal Medicine, often called the NHS women's step study [3]. The team enrolled 16,741 women from the Women's Health Study (mean age 72) and had them wear hip-worn accelerometers for seven days. They followed them for a median 4.3 years and counted deaths.

The dose-response was striking in two ways. First, the lowest-step quartile (a median of around 2,700 steps per day) had nearly three times the mortality of the highest. Second - and this is the result that drew the most attention - the benefit curve flattened sharply at about 7,500 steps per day. Going from 2,700 to 7,500 steps produced an enormous mortality reduction. Going from 7,500 to 10,000 produced essentially none. Above 10,000 there was no further benefit detectable in the data.

Crucially, the mortality reduction was not contingent on intensity. When the authors adjusted for cadence - how briskly the steps were walked - the dose-response remained strong. In this older cohort, the volume of stepping mattered more than the speed.

A year later, Saint-Maurice and colleagues published the largest NHANES-derived analysis to date: 4,840 American adults aged 40 and older, with accelerometer-measured step counts and a median 10.1 years of follow-up [4]. The pattern replicated. Mortality at 8,000 steps per day was roughly half the mortality at 4,000 steps. At 12,000 steps the hazard ratio versus 4,000 was 0.35 - a 65 percent reduction. The marginal benefit between 8,000 and 12,000 existed but was much smaller than the benefit between 4,000 and 8,000. As in the Lee 2019 paper, cadence did not change the volume-based association in any meaningful way.

The largest synthesis came in 2022, when Paluch and colleagues pooled 15 cohorts with 47,471 adults for a meta-analysis in The Lancet Public Health [5]. They confirmed the plateau pattern across cohorts and demonstrated something the single studies could not: the inflection point is age-dependent.

  • Adults aged 60 and over hit the mortality benefit plateau between 6,000 and 8,000 steps per day. The hazard ratio at 6,000 versus 2,000 was 0.58 - a 42 percent reduction.
  • Adults under 60 continued to benefit up to roughly 8,000 to 10,000 steps. The hazard ratio at 9,000 versus 3,500 was 0.49 - a 51 percent reduction.
  • In neither group did the dose-response cross 10,000 in a way that would have justified the marketing slogan. The curve was visibly flattening before that for everyone.

A 2023 European Society of Cardiology analysis led by Banach extended the picture to cardiovascular endpoints, finding mortality reductions starting at as little as 2,500 steps per day and flattening around 7,000 [6]. The headline finding from that group - that "every 1,000 steps reduced all-cause mortality by 15 percent up to 7,000" - is the cleanest single-line summary the field has produced.

Cadence: the JAMA 2022 result

The most genuinely surprising published finding in this literature is not about volume - it is about pace. In 2022, Del Pozo Cruz and colleagues published a large analysis of 78,500 UK Biobank participants with wrist-worn accelerometer data and a median 7.1 years of follow-up [7]. The team computed not just total daily steps but also a metric they called peak 30-minute cadence: the average steps-per-minute over each participant's most active continuous half-hour.

Peak 30-minute cadence predicted lower all-cause mortality and lower cancer mortality independent of total step volume. A peak cadence above roughly 80 steps per minute - a brisk walk - was associated with a 34 percent lower all-cause mortality risk versus the lowest cadence tertile, after adjusting for total steps and the usual confounders. The signal was robust to multiple sensitivity analyses.

The practical translation is that the structure of your steps matters, not just the total. A 7,000-step day that includes a brisk continuous half-hour is associated with better outcomes than a 10,000-step day made up entirely of slow ambulation between sittings. The mechanism is consistent with the broader cardiovascular literature: a brisk walking session pushes heart rate into the lower end of zone 2 and produces the vascular and mitochondrial adaptations that pure low-intensity stepping does not.

This dovetails with the broader cardiorespiratory literature. Our zone 2 cardio piece walks through why "sub-ventilatory-threshold continuous training" is so well-evidenced; cadence-based walking is the lower-end on-ramp to the same physiology. And the VO₂ max piece covers why pushing cardiorespiratory fitness even modestly upward carries some of the largest mortality effect sizes in preventive medicine.

How to actually do this

If you take the four cohorts seriously the practical implications are uncomplicated.

The threshold to target is your age-appropriate plateau. If you are over 60, aim for 7,000 to 8,000 steps as your daily floor. If you are under 60, aim for 8,000 to 10,000. Going above the plateau is not harmful, but the marginal mortality benefit is small relative to the cost in time. Use that surplus on something else - resistance training, a continuous zone 2 session, sleep.

Build in at least one brisk continuous segment. The Del Pozo Cruz cadence result implies that a single continuous half-hour at 80+ steps per minute carries a benefit independent of the total. If you are pacing yourself by feel, "brisk enough that talking in full sentences is slightly effortful" is the right ceiling. A morning or post-lunch 30-minute walk handles this cleanly.

Break up sitting, not just to hit the count. The lipoprotein-lipase and postprandial-glucose mechanisms favour distributing the steps across the day rather than batching them all into one long walk. A useful heuristic: stand and move for 2 to 5 minutes every hour during sedentary stretches. This delivers the LPL maintenance and is easier to sustain than blocking out 90 minutes of walking time.

The post-meal 10-minute walk is exceptionally high-leverage. Three short walks after the three biggest meals of the day delivers 25 to 35 percent reduction in postprandial glucose excursion and contributes roughly 2,000 steps to the daily count. This is one of the most consistently replicated low-cost interventions in metabolic health.

Treat the wearable count as a directional signal. Wrist-worn step counts undercount tasks done with one hand or with the device against a stationary surface (carrying groceries, pushing a stroller, washing dishes). Hip-worn pedometers are more accurate for raw counts but inconvenient. The Bassett group at the University of Tennessee has spent two decades validating these devices; their honest summary is that consumer wearables undercount by 5 to 25 percent depending on activity type but are highly consistent within a person across time [8]. The within-person trend is what matters, not the absolute number.

What the evidence does not support

Three claims worth flagging because they show up often and are weakly supported.

  • "You need 10,000 steps a day to be healthy." The number has no biological foundation. Every published dose-response cohort shows the benefit curve flattening between 6,000 and 8,000 for older adults and between 8,000 and 10,000 for younger ones. Hitting 10,000 daily is fine; treating it as a minimum is a misreading of the data and discourages many people from the much bigger gains available in the 2,000 to 7,000 range.
  • "Walking alone is enough; you do not need other exercise." Walking carries most of the cardiovascular and all-cause mortality benefit available from movement, but not the higher-intensity cardiorespiratory adaptation that drives VO₂ max upward, and not the progressive load that preserves muscle and bone density past the sixth decade. The strongest published combinations pair daily walking with two to three resistance sessions per week and one to two higher-intensity cardio sessions. Walking is foundational, not exclusive.
  • "More is always better." The dose-response evidence is unambiguous that there is a plateau, and above the plateau the marginal benefit of each additional step approaches zero. The opportunity cost is real - a 90-minute daily walk to hit 14,000 steps takes time that could go into resistance training, sleep, or anything else with a positive return. There is no published evidence of a U-shape (a harm from very high counts), but there is no benefit either.

The takeaway

The 10,000-step target was a 1965 marketing slogan, and the published dose-response cohorts have made it obsolete. The mortality benefit curve flattens at roughly 6,000 to 8,000 steps per day for adults over 60, and at 8,000 to 10,000 for adults under 60. Cadence - the briskness of your most active 30-minute stretch - carries a mortality signal independent of total volume, with peak cadences above 80 steps per minute associated with the strongest benefit. Distributing the steps across the day is more metabolically useful than batching them, because of the postprandial-glucose and lipoprotein-lipase mechanisms. Walking is the foundation layer; it does not replace resistance training or higher-intensity cardio, but it is the single best-evidenced daily movement variable for all-cause mortality.

If you want your daily step count, cadence, and the rest of your movement variables tracked together and rolled into a coherent bio-age picture, have a look at Thier.

Frequently asked questions

Where did the 10,000-steps-a-day target come from?

From a 1965 marketing campaign for a Japanese pedometer called the Manpo-kei - literally "10,000-step meter". The number was chosen because the Japanese character for 10,000 (万) loosely resembles a walking person, and because 10,000 was a memorable round figure. There was no underlying physiological study. Every dose-response cohort published since has found the all-cause mortality benefit plateaus well below 10,000 steps - typically between 6,000 and 8,000 for adults over 60, and between 8,000 and 10,000 for adults under 60.

What does the actual mortality data say about steps per day?

The Lee 2019 NHS women's study (16,741 women, mean age 72) found mortality fell sharply from roughly 2,700 to 7,500 steps per day, with the curve flattening above that. The Saint-Maurice 2020 NHANES analysis (4,840 adults aged 40+) found a similar dose-response, with mortality risk roughly halved at 8,000 vs 4,000 steps and little additional benefit beyond 12,000. The Paluch 2022 meta-analysis (15 cohorts, 47,471 adults) confirmed the plateau pattern and showed it shifted with age - older adults gained most of the benefit by 6,000 to 8,000 steps, while younger adults continued to benefit up to 8,000 to 10,000.

Does walking faster matter more than walking further?

Both matter, but cadence (steps per minute) carries an independent signal. The Del Pozo Cruz 2022 JAMA Internal Medicine analysis of 78,500 UK Biobank participants found that peak 30-minute cadence - the average steps-per-minute over your most active half-hour - predicted lower all-cause and cancer mortality independent of total daily step count. A peak cadence above roughly 80 steps per minute (a moderate-effort walk) carried the strongest associations. Practical translation: a 7,000-step day with a brisk 30-minute walk in it is associated with better outcomes than a 10,000-step day made entirely of slow ambulation.

Is walking enough on its own, or do I also need structured exercise?

Walking carries most of the cardiovascular and all-cause mortality benefit you can get from movement, but not all of it. The two things it does not adequately deliver are higher-intensity cardiovascular load (the kind that drives VO₂ max upward) and progressive resistance (the kind that preserves muscle mass and bone density into the seventh decade). The strongest published combinations pair daily ambulation in the 7,000 to 10,000 step range with two to three resistance sessions a week and one to two higher-intensity cardio sessions. Walking is the base layer, not the whole stack.

Do indoor steps and outdoor steps count the same?

For total step count, yes - your wearable does not know whether you are on a treadmill, in a kitchen, or on a trail. For the mortality associations, the cohort data is almost entirely based on free-living step counts measured by waist-worn accelerometers or wrist-worn devices, which capture both indoor and outdoor walking. The one subtle distinction the literature has surfaced: outdoor walking carries small additional benefits via light exposure, vitamin D synthesis, and a more variable terrain that engages stabilising musculature. The effect is real but small relative to the dose-response effect of step count itself.

References

  1. Tudor-Locke C, Bassett DR Jr. How many steps/day are enough? Preliminary pedometer indices for public health. Sports Medicine. 2004;34(1):1-8. PubMed
  2. Tudor-Locke C, Hatano Y, Pangrazi RP, Kang M. Revisiting "how many steps are enough?" Medicine & Science in Sports & Exercise. 2008;40(7 Suppl):S537-543. PubMed
  3. Lee IM, Shiroma EJ, Kamada M, Bassett DR, Matthews CE, Buring JE. Association of step volume and intensity with all-cause mortality in older women. JAMA Internal Medicine. 2019;179(8):1105-1112. PubMed
  4. Saint-Maurice PF, Troiano RP, Bassett DR Jr, et al. Association of daily step count and step intensity with mortality among US adults. JAMA. 2020;323(12):1151-1160. PubMed
  5. Paluch AE, Bajpai S, Bassett DR, et al. Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts. The Lancet Public Health. 2022;7(3):e219-e228. PubMed
  6. Banach M, Lewek J, Surma S, et al. The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis. European Journal of Preventive Cardiology. 2023;30(18):1975-1985. PubMed
  7. Del Pozo Cruz B, Ahmadi MN, Lee IM, Stamatakis E. Prospective associations of daily step counts and intensity with cancer and cardiovascular disease incidence and mortality and all-cause mortality. JAMA Internal Medicine. 2022;182(11):1139-1148. PubMed
  8. Bassett DR Jr, Toth LP, LaMunion SR, Crouter SE. Step counting: a review of measurement considerations and health-related applications. Sports Medicine. 2017;47(7):1303-1315. PubMed
  9. Stamatakis E, Ahmadi MN, Gill JMR, et al. Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality. Nature Medicine. 2022;28(12):2521-2529. PubMed
  10. Master H, Annis J, Huang S, et al. Association of step counts over time with the risk of chronic disease in the All of Us Research Program. Nature Medicine. 2022;28(11):2301-2308. PubMed